Ganglioside GT1b (GT1b) (GT1b)

Ganglioside GT1b is a complex sialic acid-containing glycosphingolipid that is highly enriched in the mammalian central and peripheral nervous systems, particularly on the presynaptic membranes of cholinergic nerve terminals (Schnaar, J Mol Biol, 2016). It belongs to the b-series of gangliosides and plays a fundamental role in maintaining neuronal membrane stability, modulating signal transduction, and facilitating cell-to-cell interactions (Lopez & Schnaar, Physiol Rev, 2009). GT1b is most notably recognized as a critical component of the dual-receptor mechanism for Clostridial neurotoxins, such as Botulinum neurotoxin (BoNT) and Tetanus toxin (TeNT), where it serves as a high-affinity primary binding site that precedes toxin internalization (Rummel, Curr Top Microbiol Immunol, 2013). In clinical medicine, GT1b is a target for therapeutic agents like Botulinum toxin type A and B, which are used to treat conditions ranging from muscle spasticity to cosmetic wrinkles by blocking acetylcholine release (Pirazzini et al., Arch Toxicol, 2022). Furthermore, GT1b is a significant autoantigen in neuroimmunological disorders; for instance, anti-GT1b antibodies are frequently detected in patients with the pharyngeal-cervical-brachial variant of Guillain-Barré syndrome and Miller Fisher syndrome (Willison et al., Lancet, 2016). Understanding the distribution and binding kinetics of GT1b is essential for developing targeted neurotherapeutics and managing autoimmune neuropathies.

Other names

Trisialoganglioside GT1bGanglioside G(T1b)II3Neu5Ac2,IV3Neu5Ac-Gg4CerGD1aGD1bPresynaptic ganglioside

Ganglioside GT1b functions as a primary attachment site for the heavy chain of Botulinum neurotoxins (BoNTs) on the presynaptic membrane. This binding concentrates the toxin on the cell surface, facilitating its interaction with a secondary protein receptor (like SV2 or Synaptotagmin), which triggers endocytosis and subsequent inhibition of neurotransmitter release (Rummel, 2013; Pirazzini et al., 2022).